At RedMedEd, increasing clinician competence and improving patient care is the name of the game.

With a track record of excellence in CME and a wide range of innovative gamification and interactive learning designs, the RedMedEd team delivers initiatives that are fresh, rigorous, engaging, and memorable.

When CME is done well, clinicians learn and patients win.

A Change of Heart (Care Practices): Recognizing and Managing Transthyretin Amyloid Cardiomyopathy

Overview Transthyretin amyloid cardiomyopathy (ATTR-CM), once considered rare, may be more prevalent than thought. Diagnosing this condition can be a challenge, as early symptoms are often attributed to aging and later, more severe, symptoms can mimic the symptoms of other conditions such as heart failure (HF) and aortic stenosis. This can be particularly problematic, as several treatments comm...
Jointly provided by Purdue University College of Pharmacy and RedMedEd

A Clinical Guide to Diagnosing and Treating Lyme Disease and Other Tick-Borne Illnesses

Overview Establishing a Lyme disease diagnosis remains a considerable challenge, as many symptoms are nonspecific and there are currently no definitive diagnostic tests available. This represents a significant clinical problem, as the number of Lyme disease cases in the U.S. is steadily increasing. This activity presents and discusses recent advances in the management of Lyme disease and other ...
Jointly provided by Postgraduate Institute for Medicine and RedMedEd, in collaboration with the State of Delaware and Global Lyme Alliance.

Myeloma Masters: The Ultimate Myeloma Patient Care Quiz Show

Keeping pace with the rapid advances in multiple myeloma patient care presents a considerable challenge to health care providers—and potentially leaves patients at a loss to understand their disease and the options available for managing it. In the format of an entertaining interactive game (think Who Wants to Be a Millionaire), this activity tests players’ knowledge of current and emerging ...
Rush University Medical Center

Shaping the Future of Myeloma Treatment

To help hematologist-oncologists keep pace with new advancements in multiple myeloma therapeutic regimens and management strategies, Shaping the Future of Myeloma Treatment features a roundtable discussion in which a panel of myeloma experts addresses a number of key clinical topics. Learners who participate in these activities will be expected to improve their ability to individualize treatment...
This CME-certified enduring activity is jointly provided by Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation.

The Evolution of Multiple Myeloma Patient Management: Managing Today, Preparing for Tomorrow

The clinical multiple myeloma arena has undergone significant advances in diagnosis and prognosis, minimal residual disease monitoring, and supportive care. This expansion brings renewed hope to patients, but it presents new challenges for the clinicians charged with their care. Some patients enjoy many years in clinical remission, whereas for others survival is no more than 2 or 3 years. This r...
Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

TKI Therapy in CML: Emerging Treatments, Ensuring Safety

This Virtual Practice summarizes advances in tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) in the context of disease- and patient-specific characteristics; reviews the most effective methods for monitoring early response and long-term therapeutic outcomes; assesses the milestones and mutational analyses to identify when a change in TKI therapy is needed; compares to...
Albert Einstein College of Medicine and RedMedEd

Treat-to-Target and Targeted Therapy: The Evolving State of Systemic Lupus Erythematosus Patient Care

The complex and varied nature of systemic lupus erythematosus (SLE) and the absence of standard therapeutic options beyond corticosteroids and systemic immunosuppressive therapy make managing this disease an extreme clinical challenge. Achieving disease remission yields positive long-term outcomes, but only 2%–7% of patients reach this goal—and then only after long-term treatment. Recent cli...
Rutgers Biomedical and Health Sciences and RedMedEd

Treating B-Cell Lymphomas: Novel Agents and the Evolving State of Practice

Over the last several decades, advances in non-Hodgkin lymphoma (NHL) management have improved survival; however, relapse and the emergence of treatment-resistant NHL following standard therapy remain ongoing treatment challenges. With conventional therapy for B-cell NHL, response rates are suboptimal and many patients relapse, highlighting the need for novel treatments that address the risk of ...
Horizon CME, the Washington State Pharmacy Association (WSPA), and RedMedEd

RXinsider,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps. RXinsider,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the Terms of Service. Site Map.